Lantern is billed as an AI platform aimed at accelerating revenue workflows, with claims of 19% increase in average deal size and automated outreach. The Champion Agent tracks job changes across the customer base to automate outreach for certain teams. Lantern Pharma reports progress in 2026, reducing R&D spend by 47% while progressing clinical programs, launching a multi-agent AI platform with Zeta.ai and expanding an AI Center of Excellence in India. These items illustrate Lantern's expansion into AI-powered drug discovery partnerships, with ongoing financing activities to support growth.
Sources
Browse, deploy, and customize AI agents that automate every critical revenue function—from champion tracking to intent monitoring, all available in minutes.
withlantern.comDisciplined Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-Agentic AI Platform withZeta.ai Commercially, and Strengthening Balance Sheet with Financing of up to $9.25 Million
natlawreview.comlantern News and Updates from The Economictimes.com
economictimes.indiatimes.comDisciplined Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-Agentic AI Platform withZeta.ai Commercially, and Strengthening Balance Sheet with Financing of up to $9.25 Million Q1 net loss reduced 27% year-over-year while progressing multiple...
www.pharmiweb.comnews
www.newswire.caLantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company leveraging its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform...
www.innovationopenlab.com